Results 91 to 100 of about 43,089 (386)
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with diverse etiologies and pathophysiological factors. Obesity and type 2 diabetes mellitus (T2DM), conditions that coexist frequently, induce a cluster of metabolic and ...
A. Elsanhoury+4 more
semanticscholar +1 more source
Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction [PDF]
Pulmonary hypertension in the setting of heart failure with preserved ejection fraction (PH-HFpEF) is a growing public health problem that is increasing in prevalence.
Gladwin, Mark T.+2 more
core +1 more source
Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu+3 more
wiley +1 more source
Dahl Salt-Sensitive (DSS) rats develop heart failure with preserved ejection fraction (HFpEF) when fed a high-salt (8 % NaCl) diet. Hypertension-induced inflammation and subsequent ventricular fibrosis are believed to underlie the development of HFpEF ...
Myung Yoon Kim+6 more
doaj +1 more source
Catheter ablation for atrial fibrillation in HFpEF patients—A propensity‐score‐matched analysis
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are both common conditions associated with high morbidity and mortality, especially if they coexist.
M. Rattka+11 more
semanticscholar +1 more source
Impact of diabetes mellitus on ventricular structure, arterial stiffness, and pulsatile hemodynamics in heart failure with preserved ejection fraction [PDF]
Background-Heterogeneity in the underlying processes that contribute to heart failure with preserved ejection fraction (HFpEF) is increasingly recognized.
Akers, Scott R.+8 more
core +2 more sources
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler+4 more
wiley +1 more source
Ahmed Hussein Subki,1 Mohammed Ali Almalki,2 Nadeem Shafique Butt,3 Mohammed Saad Alsallum,4 Hatim Mashan Almutairi,5 Hazim Abdulkarim Khatib,6 Abdulrahman Mousa Alzahrani,6 Abdullah Salem Babaker,6 Firas Abdulrahman Addas,6 Abdullah Abdulfattah Mashat,7
Subki AH+17 more
doaj
Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF
Aims Heart failure with preserved ejection fraction (HFpEF) causes substantial morbidity and mortality. Importantly, atrial remodelling and atrial fibrillation are frequently observed in HFpEF.
M. Trum+15 more
semanticscholar +1 more source
Assessing pulmonary congestion in HFpEF
Abstract
Elke Platz, Scott D Solomon
openaire +2 more sources